...
首页> 外文期刊>Journal of the Indian Medical Association. >Does Metforrnin flugment the Ovulotion Inducing effects of Clomiphene in Non-obese Women uuith Polycystic Ovary Syndrome ?
【24h】

Does Metforrnin flugment the Ovulotion Inducing effects of Clomiphene in Non-obese Women uuith Polycystic Ovary Syndrome ?

机译:二甲双胍是否会延缓克罗米芬对非肥胖多囊卵巢综合征女性的排卵诱导作用?

获取原文
获取原文并翻译 | 示例

摘要

To decide if metformin augments clomiphene response for ovulation induction in non-obese women with polycystic ovary syndrome, a prospective randomised placebo-controlled trial was undertaken among 27 patients, who were found eligible for this study following clinical assessment and basic investigations. Women with polycystic ovary syndrome, even when non-obese, has increased insulin-resistance and do not respond favourably when treated with clomiphene for ovulation induction. The hypothesis is that by improving insulin- resistance and thus reversing from hyperinsulinaemia towards normal insulin secretion will enhance the responsiveness of these women to ovulation inducing effects of clomiphene.In the metformin group there were 15 patients who were given metformin 500mg orally 8 hourly daily for initial 3 months whereas in the placebo group there were 12 patients who were given folic acid (as placebo) 5mg orally once daily for initial 3 months. Thereafter, all the 27 patients in both groups were treated with clomiphene 50mg orally once daily from day 2 for 5 days in each month for subsequent 3 months. However, metformin and folic acid was continued in the metformin group and placebo group respectively for these subsequent 3 months when these patients were being treated with clomiphene for ovulation induction. Ovulation, as the outcome measure, was assessed by serial transvaginal ultrasound scanning from day 8/ day 9 and serum progesterone estimation on the 7th or 8th day following the ultrasound evidence of ovulation. Ovulation is taken to have occurred when serum progesterone was >8ng/ml. Ovulation was noted to have occurred in 71.11 % of the 45 cycles studied in 15 patients in the metformin group whereas ovulation occurred in 11.11 % of the 36 cycles studied in 12 patients in the placebo group. This difference was highly statistically significant (p<0.001) by Fisher's exact test. It can be conducted that metformin augments the ovulation inducing effects of clomiphene in non-obese women with polycystic ovary syndrome.
机译:为了确定二甲双胍是否可增强多囊卵巢综合征非肥胖女性排卵诱导的克罗米芬反应,在27例患者中进行了一项前瞻性随机安慰剂对照试验,这些患者经过临床评估和基础研究后才有资格参与本研究。患有多囊卵巢综合征的女性即使不肥胖,其胰岛素抵抗也会增强,而用克罗米芬治疗以诱导排卵时,其反应也不佳。假设是通过改善胰岛素抵抗并从高胰岛素血症转为正常胰岛素分泌,将增强这些妇女对克罗米芬促排卵作用的反应性。二甲双胍组中有15例患者每天8小时口服二甲双胍500mg在最初的3个月中,而在安慰剂组中,有12名患者在最初的3个月中每天口服一次5mg叶酸(作为安慰剂)。此后,两组的所有27例患者均从第2天开始每天口服口服克罗米芬50mg治疗,随后每月3天,每月5天。但是,当二甲双胍组和安慰剂组接受克罗米芬治疗以诱导排卵时,在随后的三个月中,二甲双胍和叶酸分别继续存在。从第8天/第9天开始,通过连续阴道超声扫描评估排卵,作为排卵量度,并在排卵的超声证据显示第7或8天后评估血清孕酮。当血清孕酮> 8ng / ml时就认为已发生排卵。二甲双胍组的15位患者研究的45个周期中有71.11%发生了排卵,安慰剂组的12位患者的研究的36个周期中有11.11%发生了排卵。通过Fisher精确检验,该差异具有高度统计学意义(p <0.001)。可以证明,二甲双胍可增强克罗米芬对非肥胖多囊卵巢综合征女性的排卵诱导作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号